Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이현 | - |
dc.date.accessioned | 2019-05-22T07:32:55Z | - |
dc.date.available | 2019-05-22T07:32:55Z | - |
dc.date.issued | 2017-01 | - |
dc.identifier.citation | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, v. 61, no. 2, Article no. UNSP e02189-16 | en_US |
dc.identifier.issn | 0066-4804 | - |
dc.identifier.issn | 1098-6596 | - |
dc.identifier.uri | https://aac.asm.org/content/61/2/e02189-16 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/105648 | - |
dc.description.abstract | Macrolide antibiotics are cornerstones in the treatment of Mycobacterium massiliense lung disease. Despite the emergence of resistance, limited data on macrolide-resistant M. massiliense lung disease are available. This study evaluated the clinical features and treatment outcomes of patients and the molecular characteristics of macrolide-resistant M. massiliense isolates. We performed a retrospective review of medical records and genetic analyses of clinical isolates from 15 patients who had macrolide-resistant M. massiliense lung disease between September 2005 and February 2015. Nine patients (60%) had the nodular bronchiectatic form of the disease, and six (40%) had the fibrocavitary form. Before the detection of macrolide resistance, three patients (20%) were treated with macrolide monotherapy, four (27%) with therapy for presumed Mycobacterium avium complex infections, and eight (53%) with combination antibiotic therapy for M. massiliense lung disease. The median treatment duration after the detection of resistance was 18.7 months (inter-quartile range, 11.2 to 39.8 months). Treatment outcomes were poor, with a favorable outcome being achieved for only one patient (7%), who underwent surgery in addition to antibiotic therapy. The 1-, 3-, and 5-year mortality rates were 7, 13, and 33%, respectively. Of the 15 clinical isolates, 14 (93%) had point mutations at position 2058 (n = 9) or 2059 (n = 5) of the 23S rRNA gene, resulting in macrolide resistance. Our study indicates that treatment outcomes are poor and mortality rates are high after the development of macrolide resistance in patients with M. massiliense lung disease. Thus, preventing the development of macrolide resistance should be a key consideration during treatment. | en_US |
dc.description.sponsorship | This research was supported by the Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Science, ICT, and Future Planning (grant NRF-2015R1A2A1A01003959), and by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (grant HI15C2778).C.L.D. has received grants from Insmed, Inc., not associated with the submitted work. Otherwise, we have no conflicts of interest to declare. | en_US |
dc.language.iso | en | en_US |
dc.publisher | AMER SOC MICROBIOLOGY | en_US |
dc.subject | nontuberculous mycobacteria | en_US |
dc.subject | Mycobacterium massiliense | en_US |
dc.subject | macrolides | en_US |
dc.subject | drug resistance | en_US |
dc.title | Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease | en_US |
dc.type | Article | en_US |
dc.relation.no | 2 | - |
dc.relation.volume | 61 | - |
dc.identifier.doi | 10.1128/AAC.02189-16 | - |
dc.relation.page | 1-9 | - |
dc.relation.journal | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | - |
dc.contributor.googleauthor | Choi, Hayoung | - |
dc.contributor.googleauthor | Kim, Su-Young | - |
dc.contributor.googleauthor | Lee, Hyun | - |
dc.contributor.googleauthor | Jhun, Byung Woo | - |
dc.contributor.googleauthor | Park, Hye Yun | - |
dc.contributor.googleauthor | Jeon, Kyeongman | - |
dc.contributor.googleauthor | Kim, Dae Hun | - |
dc.contributor.googleauthor | Huh, Hee Jae | - |
dc.contributor.googleauthor | Ki, Chang-Seok | - |
dc.contributor.googleauthor | Lee, Nam Yong | - |
dc.relation.code | 2017002020 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | namuhanayeyo | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.